Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Biohaven Delivers Positive Phase 3 Results With Rimegepant Zydis® Orally Dissolving Tablet (odt): Rapid And Lasting Benefit For The Acute Treatment Of Migraine
LPNEWS

Biohaven Delivers Positive Phase 3 Results With Rimegepant Zydis® Orally Dissolving Tablet (odt): Rapid And Lasting Benefit For The Acute Treatment Of Migraine

by prnewswire.com posted 3months ago 195 views
NEW HAVEN, Conn., Dec. 3, 2018 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced positive topline results from a randomized, controlled Phase 3 clinical trial (BHV3000-303 or Study 303) evaluating the efficacy and safety of its Zydis® orally...

In this article